NASDAQ:CBIO

Catalyst Biosciences Stock Insider Trading

> Biotechnology

Buy CBIO

*Your capital is at risk

$17.98

+0.98 (+5.73%)

At Close: Jun 03, 2026

Catalyst Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.31. In total, the insiders bought 7.12M and sold 4.54M CBIO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.31
● Buy	7.12M shares
● Sell	4.54M shares
82% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.31. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (82% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 15, 2025 Buy	Ordinary Shares A-Award	Im Ellie Eunkyung Chief Medical Officer	Officer	16 298 Value: $215.0K
Dec 15, 2025 Buy	Stock Option (Right to Buy) A-Award	Bispham Barbara Harlin See Remarks	Officer	72 185 Value: $953.6K
Dec 15, 2025 Buy	Ordinary Shares A-Award	Bispham Barbara Harlin See Remarks	Officer	6 000 Value: $79.1K
Dec 15, 2025 Buy	Ordinary Shares A-Award	Bispham Barbara Harlin See Remarks	Officer	12 422 Value: $163.8K
Dec 08, 2025 Buy	Stock Option (Right to Buy) A-Award	Brumm Joshua T Chief Executive Officer	CEO / President	345 672 Value: $4.55M
Dec 08, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcneill Jonathan President And COO	CEO / President	172 836 Value: $2.28M
Dec 04, 2025 Buy	Ordinary Shares P-Purchase	Fairmount Funds Management Llc	Director	1 360 000 Value: $18.2M
Dec 04, 2025 Buy	Pre-Funded Warrant (Right to Buy) P-Purchase	Fairmount Funds Management Llc	Director	131 434 Value: $131
Jul 16, 2025 Buy	Stock Option (Right to Buy) A-Award	Pinkas Jan Chief Scientific Officer	Officer	142 474 Value: $1.87M
Jul 16, 2025 Buy	Stock Option (Right to Buy) A-Award	Pinkas Jan Chief Scientific Officer	Officer	142 474 Value: $1.87M
Jul 07, 2025 Buy	Common Stock J-Other	Pinkas Jan Officer	Officer	0 Value: $0
Jul 07, 2025 Buy	Common Stock J-Other	Pinkas Jan Officer	Officer	0 Value: $0
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Moran Susan Director	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Fairmount Funds Management Llc	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Violin Jonathan Director	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Balcom Alexandra Director	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Lubner David Charles Director	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Lubner David Charles Director	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Balcom Alexandra Director	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Violin Jonathan Director	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Fairmount Funds Management Llc	Director	9 023 Value: $138.1K
Jun 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Moran Susan Director	Director	9 023 Value: $138.1K
Aug 08, 2024 Sell	Common Stock S-Sale	Invus Public Equities, L.p. 10 Percent Owner	10% Owner	260 873 Value: $50.0K
Aug 08, 2024 Sell	Common Stock S-Sale	Invus Public Equities, L.p. 10 Percent Owner	10% Owner	260 873 Value: $50.0K
Aug 07, 2024 Sell	Common Stock S-Sale	Invus Public Equities, L.p. 10 Percent Owner	10% Owner	61 488 Value: $11.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CATALYST BIOSCIENCES INC

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD);...

Read Full Profile Here